Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse

BACKGROUND: Despite treatment with high-dose chemotherapy followed by autologous stem cell transplantation (AHCT), patients with multiple myeloma (MM) invariably relapse. Molecular residual disease (MRD)-negativity post-AHCT has emerged as an important prognostic marker predicting the duration of re...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhakal, Binod, Sharma, Shruti, Balcioglu, Mustafa, Shchegrova, Svetlana, Malhotra, Meenakshi, Zimmermann, Bernhard, Billings, Paul R., Harrington, Alexandra, Sethi, Himanshu, Aleshin, Alexey, Hari, Parameswaran N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848740/
https://www.ncbi.nlm.nih.gov/pubmed/35186734
http://dx.doi.org/10.3389/fonc.2022.786451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848740/
https://www.ncbi.nlm.nih.gov/pubmed/35186734
http://dx.doi.org/10.3389/fonc.2022.786451

Ejemplares similares